Karuna Therapeutics Inc. (KRTX) Confirms Proposed 2.6M Share Public Offering of Common Stock

Go back to Karuna Therapeutics Inc. (KRTX) Confirms Proposed 2.6M Share Public Offering of Common Stock

Karuna Therapeutics Announces Proposed Public Offering of Common Stock

November 18, 2019 4:21 PM EST

BOSTON--(BUSINESS WIRE)-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000 shares of its common stock. Karuna intends to grant the underwriters a 30-day option to purchase an additional 390,000 shares of its common stock, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and... More

Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

November 18, 2019 6:00 AM EST

KarXT Demonstrated Statistically Significant and Clinically Meaningful Improvement in Total PANSS Score at All Time Points Over Five Weeks and was Well-Tolerated Compared to Placebo

Improvement in Total PANSS Score at Five Weeks was 11.6 Points Compared to Placebo (p... More